Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | BRS3 | P32247 | 2/20 | 0.36 |
| ▸ | ATP4A | P20648 | 9/20 | 0.36 |
| ▸ | ATP4B | P51164 | 9/20 | 0.36 |
| ▸ | ATP1A1 | P05023 | 6/20 | 0.36 |
| ▸ | ATP1B1 | P05026 | 6/20 | 0.36 |
| ▸ | ATP1A3 | P13637 | 6/20 | 0.36 |
| ▸ | ATP1B2 | P14415 | 6/20 | 0.36 |
| ▸ | ATP1A2 | P50993 | 6/20 | 0.36 |
| ▸ | ATP1B3 | P54709 | 6/20 | 0.36 |
| ▸ | FXYD2 | P54710 | 6/20 | 0.36 |
| ▸ | ATP1A4 | Q13733 | 6/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | WDR5 | P61964 | 3/20 | 0.35 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.35 |
| ▸ | ENGASE | Q8NFI3 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6881054 | 0.93 | RUNX1 (0.38) | CYP2C9BRS3ATP4AATP4BATP1A1 | |
| SCHEMBL6873282 | 0.90 | ATP4A (0.44) | CYP2C9BRS3ATP4AATP4BATP1A1 | |
| SCHEMBL21671227 | 0.89 | BRS3 (0.45) | CYP2C9BRS3ATP4AATP4BATP1A1 | |
| SCHEMBL6884504 | 0.88 | ATP4A (0.43) | CYP2C9BRS3ATP4AATP4BATP1A1 | |
| SCHEMBL6879493 | 0.88 | ATP4A (0.46) | CYP2C9BRS3ATP4AATP4BATP1A1 | |
| SCHEMBL6872824 | 0.87 | ATP4A (0.49) | CYP2C9BRS3ATP4AATP4BATP1A1 | |
| SCHEMBL23988599 | 0.86 | BRS3 (0.43) | CYP2C9BRS3ATP4AATP4BATP1A1 | |
| SCHEMBL23988275 | 0.86 | BRS3 (0.43) | CYP2C9BRS3ATP4AATP4BATP1A1 | |
| SCHEMBL9527196 | 0.86 | BRS3 (0.43) | CYP2C9BRS3ATP4AATP4BATP1A1 | |
| SCHEMBL6881153 | 0.85 | ATP4A (0.44) | CYP2C9ATP4AATP4BATP1A1ATP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | ATOPIX THERAPEUTICS LTD (GB) | 2014-11-06 | — | — | US | disclosed |
| EP-2790696-A1 | COMBINATION OF CRTH2 ANTAGONIST AND A PROTON PUMP INHIBITOR FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS | Atopix Therapeutics Limited (GB) | 2014-10-22 | — | — | EP | disclosed |
| WO-2013088109-A1 | COMBINATION OF CRTH2 ANTAGONIST AND A PROTON PUMP INHIBITOR FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS | OXAGEN LIMITED (GB) | 2013-06-20 | — | — | WO | disclosed |
| US-20040258621-A1 | Method of treating snoring and other obstructive breathing disorders | SOHNSTEARNS & STERN | 2004-12-23 | — | — | US | disclosed |
| EP-0166287-B1 | DIALKOXYRIDINES, PROCESS FOR THEIR PREPARATION, THEIR APPLICATION AND MEDICAMENTS CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1989-08-23 | — | — | EP | disclosed |
| US-4758579-A | e.g. pantoprazole or pantoprazole sodium | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1988-07-19 | — | — | US | disclosed |
| EP-0166287-A1 | Dialkoxyridines, process for their preparation, their application and medicaments containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1986-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040258621-A1 | Method of treating snoring and other obstructive breathing disorders | HRH2, HRH1, HRH4 | CYP2C9 1227/4885BRS3 56/4885ATP4A 298/4885 |
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | HRH2, HRH1, HRH4 | CYP2C9 2737/4885BRS3 203/4885ATP4A 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.